Tag: LQT Therapeutics

LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT syndrome

Rhythm by 0 comments

Closing the gap between industry and academia to place patients directly at the center of research efforts. , Jan. 6, 2022 /PRNewswire/ – LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project “SILENCE-LQTS: SGK1 inhibition as a novel therapeutic approach in Long QT syndrome” was selected for […]

Continue Reading →

LQT Therapeutics Announces Closing of US$19M Series A Financing to Advance Lead Compound Through Phase 1 while Advancing Portfolio Assets

Financial by 0 comments

–  Company established with world-class research from leading academia and industry leaders–  Lead program targets a novel kinase involved in cellular stress response  –  Experienced and proven team advancing therapies for Long QT Syndrome and resistant cancers LAVAL, QC, Aug. 10, 2021 /PRNewswire/ – LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the […]

Continue Reading →